Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Portunus trituberculatus phospholipids (Pt-PL) are a natural product extract derived from the eggs of the crab, Portunus trituberculatus. This complex mixture primarily contains various phospholipids, including phosphatidylcholine (PC), phosphatidylserine (PS), phosphatidic acid (PA), phosphatidylethanolamine (PE), and phosphatidylinositol (PI). It is also rich in polyunsaturated fatty acids (PUFAs), such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Pt-PL has demonstrated anti-obesity effects and the ability to regulate gut microbiota in high-fat diet-fed mice, suggesting its potential as a food supplement for managing obesity and promoting human gut health.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Portunus trituberculatus phospholipids.